

Twenty-third Meeting of the Technical Advisory Group on Immunization and Vaccine-preventable Diseases in the Western Pacific Region



16–20 June 2014
Manila, Philippines



**23rd MEETING OF THE TECHNICAL ADVISORY GROUP ON IMMUNIZATION AND VACCINE - PREVENTABLE DISEASES
IN THE WESTERN PACIFIC REGION
17 - 20 June 2014, Manila, Philippines**

RS/2014/GE/21(PHL)

English only

REPORT

TWENTY-THIRD MEETING OF THE TECHNICAL ADVISORY GROUP ON IMMUNIZATION AND VACCINE-PREVENTABLE DISEASES IN THE WESTERN PACIFIC

Manila, Philippines
16–20 June 2014

Convened by

**WORLD HEALTH ORGANIZATION
REGIONAL OFFICE FOR THE WESTERN PACIFIC**

Not for Sale

Printed and distributed by:

World Health Organization
Regional Office for the Western Pacific
Manila, Philippines

April 2015

NOTE

The views expressed in this report are those of the participants of the Twenty-third Meeting of the Technical Advisory Group on Immunization and Vaccine-Preventable Diseases in the Western Pacific and do not necessarily reflect the policies of the Organization.

The Expanded Programme on Immunization, WHO Regional Office for the Western Pacific, would like to thank the Ministry of Health, Labour and Welfare of Japan for providing financial support for the meeting, including the production of this report.

This report has been prepared by the World Health Organization Regional Office for the Western Pacific for the participants of the Twenty-third Meeting of the Technical Advisory Group on Immunization and Vaccine-Preventable Diseases in the Western Pacific, which was held in Manila, Philippines, from 16 to 20 June 2014.

ABBREVIATIONS

AEFI	adverse events following immunization
AFP	acute flaccid paralysis
BOPV	bivalent oral polio vaccine
CDIBP	Chengdu Institute of Biological Products
CRS	congenital rubella syndrome
CTC	controlled temperature chain
DTP	diphtheria, tetanus and pertusis
DTP3	three doses of diphtheria, tetanus and pertussis
ELISA	enzyme-linked immunosorbent assays
EQA	external quality assessment
ERP	Expert Resource Panel
Gavi	Gavi, the Vaccine Alliance
GVAP	Global Vaccine Action Plan
Hib	Haemophilus influenzae type b
HPV	human papillomavirus
HRC	high-risk community
IBVPD	invasive bacterial vaccine-preventable disease
IGM	immunoglobuline m
IPV	Inactivated polio vaccine
ITD	intratypic differentiation
JE	Japanese encephalitis
JRF	Joint Reporting Form
KCDC	Korea Centers for Disease Control and Prevention
LB	live births
LQA-CS	lot quality assurance-cluster survey
MCV	measles-containing vaccine
MCV1	first dose of measles-containing vaccine
MCV2	second dose of measles-containing vaccine
MI	mass immunization
MMR	measles, mumps and rubella
MMR-2	second dose of measles, mumps and rubella
MNT	maternal and neonatal tetanus
MNTE	maternal and neonatal tetanus elimination
MR	measles rubella
NCL	national control laboratory
NIHE	National Institute of Hygiene and Epidemiology
NITAGS	National Immunization Technical Advisory Groups
NRA	national regulatory authority
NT	neonatal tetanus
NVC	National Verification Committee
OPV	oral polio vaccine
OPV2	second dose of oral polio vaccine
ORI	outbreak response immunization
PCR	polymerase chain reaction
PCV	pneumococcal conjugate vaccine
PICS	Pacific island countries and areas
PIE	post-introduction evaluation
PT	proficiency testing
RCA	rapid coverage assessment

RCC	Regional Certification Commission
RCM	Regional Committee Meeting
RCV	rubella-containing vaccine
RCV1	first dose of rubella-containing vaccine
RED	Reaching every district
RRL	regional reference laboratory
RVC	Regional Verification Commission
SAGE	Strategic Advisory Group of Experts
SIA	supplementary immunization activity
SMS	short message service
TAG	Technical Advisory Group on Immunization and Vaccine-Preventable Diseases
TOPV	trivalent oral polio vaccine
TT	tetanus toxoid
UNICEF	United Nations Children's Fund
US CDC	United States Centers for Disease Control and Prevention
VDPV	vaccine-derived poliovirus
VPD	vaccine-preventable disease

CONTENTS

SUMMARY	6
1. INTRODUCTION.....	2
1.1 Objectives	2
1.2 Organization	2
1.3 Opening remarks.....	2
2. PROCEEDINGS	2
2.1 Global update on Global Vaccine Action Plan.....	2
2.2 Expanded Programme on Immunization in the Western Pacific Regional overview	3
2.3 Measles elimination	4
2.3.1 Global overview	4
2.3.2 Regional overview	5
2.3.3 Countries verified for elimination – issues and plan for response	7
2.3.4 Countries with resurgence after low incidence – issues and plan for response	8
2.3.5 Countries with endemic transmission – issues and plan for response.....	10
2.4 Polio eradication and endgame	12
2.4.1 Global update on polio endgame strategy	12
2.4.2 Polio eradication and polio endgame strategy in the Western Pacific Region.....	12
2.5 Rubella and Congenital Rubella Syndrome (CRS) elimination	14
2.5.1 Global overview	14
2.5.2 Regional overview	15
2.5.3 Country experiences.....	16
2.5.4 Country experiences towards rubella and CRS elimination.....	18
2.6 Hepatitis B accelerated control	21
2.6.1 Regional update	21
2.6.2 Expert Resource Panel's recommendations.....	21
2.6.3 New regional plan	22
2.6.4 Role of Regional Hepatitis B Laboratory Network.....	22
2.7 Japanese encephalitis accelerated control.....	22
2.7.1 Overview	22
2.7.2 Country Experiences	23
2.8 Maternal and neonatal tetanus elimination	25
2.8.1 Global and regional overview	25
2.8.2 Country experiences.....	26
2.9 Evidence-based introduction of new vaccines	28
2.9.1 Global and regional overview of new vaccine policy, introduction, and evaluation ...	28
2.9.2 Invasive bacterial vaccine-preventable diseases and rotavirus laboratory network update	28
2.9.3 Country experiences.....	29
2.10. Immunization targets	30

2.10.1 Regional overview	30
2.10.2 Measuring programme performance, the need for better data, global overview	30
2.10.3 Country experience	31
2.11 Review of selected actions to implementing GVAP strategic objectives in the Western Pacific Region.....	31
2.11.1 Engage individuals and communities on the benefits of immunization.....	31
2.11.2 Ensure capacity for vaccine safety activities	32
2.11.3 Strengthen NRA.....	33
2.11.4 Commitment to invest in immunization.....	34
2.12 Interagency Coordinating Committee Meeting	35
3. CONCLUSIONS AND RECOMMENDATIONS.....	35
3.1 Measles elimination	35
3.2 Polio eradication	38
3.3 Rubella elimination.....	39
3.4 Hepatitis B eontrol.....	41
3.5 Accelerated eontrol of Japanese encephalitis	42
3.6 Maternal and neonatal tetanus elimination	42
3.7 Evidence-based introduction of new vaccines.....	43
3.8 Meeting regional vaccination coverage targets	44
3.9 Regional Framework for Implementation of the Global Vaccine Action Plan in the Western Pacific 2013–2020	44

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27809

